The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease
Open accessAbstract
Apolipoprotein C-III (apoC-III) is a marker of triglyceride (TG)-rich lipoproteins, which are often increased in metabolic syndrome (MS). The T-455C polymorphism in the insulin-responsive element of the APOC3 gene influences TG and apoC-III levels. To evaluate the contribution of apoC-III levels and T-455C polymorphisms in the coronary artery disease (CAD) risk of MS patients, we studied 873 patients, 549 with CAD and 251 with normal coronary arteries. Patients were classified also as having or not having MS (MS, n = 270; MS-free, n = 603). Lipids, insulin, apolipoprotein levels, and APOC3 T-455C genotypes were evaluated. ApoC-III levels were significantly increased in MS patients, and the probability of having MS was correlated with increasing quartiles of apoC-III levels. MS patients with CAD had significantly higher apoC-III levels than did CAD-free MS patients. The carriership for the -455C variant multiplied the probability of CAD in MS in an allele-specific way and was associated with increased apoC-III and TG levels. Obesity was less frequent in MS carriers of the -455C allele than in MS noncarriers (21.6% vs. 34.8%, P < 0.05). In conclusion, apoC-III-rich lipoprotein metabolism and the APOC3 polymorphism have relevant impacts on the CAD risk of MS patents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous studies have suggested that two single-nucleotide polymorphisms (SNPs) in the gene encoding apolipoprotein C3 (APOC3) may be associated with hypertriglyceridemia.4–8”
From Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease (2010) · cites this paper as [5]
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Ford, E. S., Giles, W. H., & Dietz, W. H. (2002) · JAMA · doi:10.1001/jama.287.3.356 · Cited by 6,698
Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome
Isomaa, B., Almgren, P., Tuomi, T., Forsén, B., Lahti, K., Nissén, M., Taskinen, M.-R., & Groop, L. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.683 · Cited by 4,760
Insulin resistance and cardiovascular disease
Ginsberg, H. N. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10762 · Cited by 1,372
An Apolipoprotein Influencing Triglycerides in Humans and Mice Revealed by Comparative Sequencing
Pennacchio, L. A., Olivier, M., Hubacek, J. A., Cohen, J. C., Cox, D. R., Fruchart, J.-C., Krauss, R. M., & Rubin, E. M. (2001) · Science · doi:10.1126/science.1064852 · Cited by 921
Role of apoCs in lipoprotein metabolism: functional differences between apoC1, apoC2, and apoC3
Jong, M. C., Hofker, M. H., & Havekes, L. M. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.3.472 · Cited by 539
Sacks, F. M., Alaupovic, P., Moye, L. A., Cole, T. G., Sussex, B., Stampfer, M. J., Pfeffer, M. A., & Braunwald, E. (2000) · Circulation · doi:10.1161/01.cir.102.16.1886 · Cited by 490
Ginsberg, H. N., Le, N. A., Goldberg, I. J., Gibson, J. C., Rubinstein, A., Wang-Iverson, P., Norum, R., & Brown, W. V. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112713 · Cited by 424 · cited 1×
“ApoC-III inhibits the hydrolysis of TG-rich particles by the lipoprotein lipase and their hepatic uptake mediated by apoE (9, 10 ).”
BackgroundObesity, Metabolic Syndrome, and Coronary Atherosclerosis
Grundy, S. M. (2002) · Circulation · doi:10.1161/01.cir.0000020650.86137.84 · Cited by 380
Talmud, P. J. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.24.3039 · Cited by 365
Hodis, H. N., Mack, W. J., Azen, S. P., Alaupovic, P., Pogoda, J. M., LaBree, L., Hemphill, L., Kramsch, D. M., & Blankenhorn, D. H. (1994) · Circulation · doi:10.1161/01.cir.90.1.42 · Cited by 321
Blankenhorn, D. H., Alaupovic, P., Wickham, E., Chin, H. P., & Azen, S. P. (1990) · Circulation · doi:10.1161/01.cir.81.2.470 · Cited by 278
Li, W. W., Dammerman, M. M., Smith, J. D., Metzger, S., Breslow, J. L., & Leff, T. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118324 · Cited by 278
The Metabolic Syndrome, LDL Particle Size, and Atherosclerosis
Hulthe, J., Bokemark, L., Wikstrand, J., & Fagerberg, B. (2000) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.20.9.2140 · Cited by 249
Zimmet, P., Boyko, E. J., Collier, G. R., & de Courten, M. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb07783.x · Cited by 234
Groop, L., & Orho‐Melander, M. (2001) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2001.00864.x · Cited by 233
Dammerman, M., Sandkuijl, L. A., Halaas, J. L., Chung, W. K., & Breslow, J. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.10.4562 · Cited by 226
Chen, M., Breslow, J. L., Li, W., & Leff, T. (1994) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39938-7 · Cited by 183
Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III.
Wj, M., Gesquière, J. C., Bass, H. B., Tartar, A. L., Fruchart, J., & Wang, C. (1992) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41415-4 · Cited by 176
Lipoprotein Subclasses in the Monitored Atherosclerosis Regression Study (MARS)
Mack, W. J., Krauss, R. M., & Hodis, H. N. (1996) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.16.5.697 · Cited by 173
Chan, D. C., Watts, G. F., Redgrave, T. G., Mori, T. A., & Barrett, P. H. R. (2002) · Metabolism · doi:10.1053/meta.2002.33339 · Cited by 137
Markers of triglyceride-rich lipoprotein remnant metabolism in visceral obesity
Chan, D. C., Watts, G. F., Barrett, P. H., Mamo, J. C., & Redgrave, T. G. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.2.278 · Cited by 117
Luc, G., Fievet, C., Arveiler, D., Evans, A. E., Bard, J. M., Cambien, F., Fruchart, J. C., & Ducimetiere, P. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37594-5 · Cited by 114
Polymorphic Markers in Apolipoprotein C-III Gene Flanking Regions and Hypertriglyceridemia
Surguchov, A. P., Page, G. P., Smith, L. C., Patsch, W., & Boerwinkle, E. (1996) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.16.8.941 · Cited by 110
Wong, W.-M. R., Hawe, E., Li, L. K., Miller, G. J., Nicaud, V., Pennacchio, L. A., Humphries, S. E., & Talmud, P. J. (2003) · Circulation Research · doi:10.1161/01.res.0000069688.94567.7a · Cited by 84
Triglycerides, apo C3 and Lp B:C3 and cardiovascular risk in Type II diabetes
Gervaise, N., Garrigue, M. A., Lasfargues, G., & Lecomte, P. (2000) · Diabetologia · doi:10.1007/s001250051366 · Cited by 82
Common Genomic Variation in theAPOC3Promoter Associated With Variation in Plasma Lipoproteins
Hegele, R. A., Connelly, P. W., Hanley, A. J., Sun, F. Y., Harris, S. B., & Zinman, B. (1997) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.17.11.2753 · Cited by 75
ApoC-III gene polymorphisms and risk of coronary artery disease
Olivieri, O., Stranieri, C., Bassi, A., Zaia, B., Girelli, D., Pizzolo, F., Trabetti, E., Cheng, S., Grow, M. A., Pignatti, P. F., et al. (2002) · Journal of Lipid Research · doi:10.1194/jlr.m200145-jlr200 · Cited by 70
Self-citationShoulders, C. C., Grantham, T. T., North, J. D., Gaspardone, A., Tomai, F., de Fazio, A., Versaci, F., Gioffrè, P. A., & Cox, N. J. (1996) · Human Genetics · doi:10.1007/s004390050259 · Cited by 60
Accumulation of Triglyceride-Rich Lipoprotein in Subjects With Abdominal Obesity
Bard, J., Charles, M.-A. A., Juhan-Vague, I., Vague, P., André, P., Safar, M. E., Fruchart, J., & Eschwège, É. (2001) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.21.3.407 · Cited by 39
Tilly, P., Sass, C., Vincent‐Viry, M., Aguillon, D., Siest, G., & Visvikis‐Siest, S. (2003) · Journal of Lipid Research · doi:10.1194/jlr.m200006-jlr200 · Cited by 37
Jamshidi, Y., Flavell, D. M., Hawe, E., MacCallum, P. K., Meade, T. W., & Humphries, S. E. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(02)00002-3 · Cited by 24
Gr, T. (1998) · PubMed · Cited by 17
Attia, N., Durlach, V., Cambilleau, M., Roche, D., & Girard-Globa, A. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(99)00337-8 · Cited by 14
Cited by
Sorted by citations
The Human Obesity Gene Map: The 2005 Update
Rankinen, T., Zuberi, A., Chagnon, Y. C., Weisnagel, S. J., Argyropoulos, G., Walts, B., Pérusse, L., & Bouchard, C. (2006) · Obesity · doi:10.1038/oby.2006.71 · Cited by 1,119
Progress and Challenges in Metabolic Syndrome in Children and Adolescents
Steinberger, J., Daniels, S. R., Eckel, R. H., Hayman, L. L., Lustig, R. H., McCrindle, B. W., & Mietus‐Snyder, M. (2009) · Circulation · doi:10.1161/circulationaha.108.191394 · Cited by 721
Pathophysiology of diabetic dyslipidaemia: where are we?
Vergès, B. (2015) · Diabetologia · doi:10.1007/s00125-015-3525-8 · Cited by 708
Fruchart, J.-C., Sacks, F., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.10.002 · Cited by 463
Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease
Petersen, K. F., Dufour, S., Hariri, A., Nelson-Williams, C., Foo, J. N., Zhang, X.-M., Dziura, J., Lifton, R. P., & Shulman, G. I. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907295 · Cited by 428
Metadata
- Authors
- Olivieri, O., Bassi, A., Stranieri, C., Trabetti, E., Martinelli, N., Pizzolo, F., Girelli, D., Friso, S., Pignatti, P. F., & Corrocher, R.
- Affiliations
- University of Verona (IT)
- Corresponding author
- Olivieri, Oliviero
- ORCID
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2003-12
- Volume
- 44
- Issue
- 12
- Pages
- 2374-2381
- ISSN
- 0022-2275 (ISSN-L)
- OpenAlex
- W2125644926
- Cited by
- 139
- References
- 36
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 2 · 2023: 3 · 2022: 10 · 2021: 2 · 2020: 1 · 2018: 3 · 2017: 6 · 2016: 6 · 2015: 9 · 2014: 6 · 2013: 11 · 2012: 2
- FWCI
- 5.94
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Lipid Research (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- apolipoprotein C-III, metabolic syndrome, coronary artery disease, triglyceride-rich lipoproteins, triglycerides, genetic susceptibility, obesity
- MeSH terms
- Adult, Alleles, Apolipoproteins C, Coronary Artery Disease, Data Interpretation, Statistical, Female, Genotype, Humans, Lipids, Male, Middle Aged, Polymorphism, Genetic, Substrate Specificity, Biomarkers, Odds Ratio, Genetic Predisposition to Disease, Metabolic Syndrome, Apolipoprotein C-III
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
